BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37735104)

  • 21. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.
    Tomlinson MG; Kurosaki T; Berson AE; Fujii GH; Johnston JA; Bolen JB
    J Biol Chem; 1999 May; 274(19):13577-85. PubMed ID: 10224128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.
    Takata M; Kurosaki T
    J Exp Med; 1996 Jul; 184(1):31-40. PubMed ID: 8691147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Moyo TK; Wilson CS; Moore DJ; Eischen CM
    Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bruton's tyrosine kinase regulates B cell antigen receptor-mediated JNK1 response through Rac1 and phospholipase C-gamma2 activation.
    Inabe K; Miyawaki T; Longnecker R; Matsukura H; Tsukada S; Kurosaki T
    FEBS Lett; 2002 Mar; 514(2-3):260-2. PubMed ID: 11943162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.
    Wahl MI; Fluckiger AC; Kato RM; Park H; Witte ON; Rawlings DJ
    Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11526-33. PubMed ID: 9326643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
    Buhl AM; Cambier JC
    J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis.
    Neys SFH; Heukels P; van Hulst JAC; Rip J; Wijsenbeek MS; Hendriks RW; Corneth OBJ
    Cells; 2021 May; 10(6):. PubMed ID: 34073225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction.
    Fujimoto M; Poe JC; Satterthwaite AB; Wahl MI; Witte ON; Tedder TF
    J Immunol; 2002 Jun; 168(11):5465-76. PubMed ID: 12023340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New roles for B cell receptor associated kinases: when the B cell is not the target.
    Nguyen PH; Niesen E; Hallek M
    Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
    Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
    Front Immunol; 2018; 9():2027. PubMed ID: 30237801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
    Dhami K; Chakraborty A; Gururaja TL; Cheung LW; Sun C; DeAnda F; Huang X
    Sci Signal; 2022 May; 15(736):eabg5216. PubMed ID: 35639855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.
    Kouro T; Nagata K; Takaki S; Nisitani S; Hirano M; Wahl MI; Witte ON; Karasuyama H; Takatsu K
    Int Immunol; 2001 Apr; 13(4):485-93. PubMed ID: 11282988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
    Craxton A; Jiang A; Kurosaki T; Clark EA
    J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin.
    Kenny EF; Quinn SR; Doyle SL; Vink PM; van Eenennaam H; O'Neill LA
    PLoS One; 2013; 8(8):e74103. PubMed ID: 23967355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
    Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.